Dietary fibre as a modulator of airway inflammation in asthma

Phase 2

Completed

• Conditions: Asthma; Respiratory - Asthma

• Registration Number: ACTRN12615000368538
• Lead Sponsor: A/Prof Lisa Wood

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-22
• Study Completion: 2016-02-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

Doctor diagnosed stable asthma
Aged 18+ years
Males and Females
Never or ex-smokers (6 months minimum cessation)

Exclusion Criteria

Smoking, pregnant/breastfeeding, Asthma is not the primary respiratory diagnosis, Asthma exacerbation or respiratory tract infection (oral corticosteroids or antibiotics) in the past month, Any use of antibiotics in the past month, unable or unwilling to modify diet, diagnosed bowel disorders or intestinal disorders, dietary or nutritional supplement use within the previous 4 weeks, current use of any oral medication known to significantly influence inflammation (eg statins or NSAIDs). Subject has a clinically important medical illness (including serious psychological disorders) likely to interfere with management or participation in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Plasma short chain fatty acids (SCFA) will be measured before and after each phase of the study.[Change in SCFA after 7 days of each treatment arm compared to placebo.]

Secondary Outcome Measures

Name	Time	Method
Systemic Inflammation (Plasma CRP & TNFa)[Change in Plasma CRP & TNFa after 7 days of each treatment arm compared to placebo.];Airway Inflammation (sputum cell counts, IL-8, FeNO)[Change in sputum cell counts, IL-8 and FeNO after 7 days of each treatment arm compared to placebo];Faecal SCFA[Change in faecal SCFA after 7 days of each treatment arm compared to placebo.]